Drugs / OCN19-overexpressed Human Umbilical Cord-derived Mesenchymal Stem Cells
OCN19-overexpressed Human Umbilical Cord-derived Mesenchymal Stem Cells
Cell therapy targets INS via activation
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06727721 | Nov 2023 → Dec 2028 expected | type 2 diabetes mellitus | Lu jin ，MD | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OCN19-overexpressed Human Umbilical Cord-derived Mesenchymal Stem Cells | “OCN19-overexpressed Human Umbilical Cord-derived Mesenchymal Stem Cells” NCT06727721 ↗ |
| Action | Activate | “directly stimulate the expression of insulin gene” NCT06727721 ↗ |
| Modality | Cell therapy | “mesenchymal stem cells with OCN-19” NCT06727721 ↗ |
| Target | INS | “directly stimulate the expression of insulin gene” NCT06727721 ↗ |